# Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

> **NCT06479954** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Relapsed and Refractory Multiple Myeloma (RRMM)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06479954
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-30
- **Primary completion:** 2027-02-25
- **Final completion:** 2027-02-25
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06479954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06479954, "Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06479954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*